MedTrace Logo

Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus

NCT00694057 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2011-06-14

No results posted yet for this study

Summary

This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or placebo) for a treatment period of 12-weeks.

Conditions

Interventions

DRUG

HE3286

HE3286 10 mg per day (5 mg BID)

DRUG

Placebo

Placebo capsules BID

Sponsors & Collaborators

  • Harbor Therapeutics

    lead INDUSTRY

Principal Investigators

  • Dwight R. Stickney, MD · Harbor Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00694057 on ClinicalTrials.gov